Raunatin [Rauwolfia alkaloids]
Health Pharmaceutical Company
631 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Rauwolfia alkaloids have a hypotensive and antiarrhythmic effect. The sedative effect is less pronounced than that of reserpine, but, due to the hypotensive effect, they are almost as good as reserpine, and in some cases are better tolerated.
The hypotensive effect of Raunatin develops more slowly than that of reserpine.
Indications
Arterial hypertension mild to moderate severity.
Composition
Active substance: Rauwolfia alkaloids 2 mg.
No customer reviews for the moment.
Dosage and Administration
Raunatin is taken orally after meals. On the 1st day, take 1 pill (2 mg - in terms of the amount of alkaloids) at night; on the 2nd day - 1 tablet 2 times a day, on the 3rd day - 3 tablets, gradually increasing the total dose to 4-6 tablets per day.
After reaching a therapeutic effect (after 10-14 days), the dose is gradually reduced to 1-2 tablets per day.
Adverse reactions
maybe swelling of the nasal mucosa, increased sweating, asthenia, cardialgia, bradycardia, depression, decreased libido.
Contraindications
- hypotension;
- depression;
- insufficiency of coronary circulation;
- organic lesions of the myocardium;
- aortic defects;
- stomach ulcer and duodenal ulcer;
- nephrosclerosis;
- pregnancy (III trimester);
- age up to 18 years;
- hypersensitivity to rauwolfia alkaloids.
Drug interactions
With caution prescribed together with quinidine, guanethidine, cardiac glycosides, beta-blockers (the risk of increased severity of negative chrono-and dromotropic action).
Pregnancy and Lactation
Contraindicated in pregnancy (III trimester), during lactation.
Special instructions
Perhaps simultaneous or sequential use with other antihypertensive drugs (ganglioblokatorami, hydrochlorothiazide, hydralazine).
Overdosage
Symptoms: sweating, general weakness and severe hypotension. In severe cases, after a short period of euphoria, drowsiness, depression, hypodynamia, symptoms of marked parkinsonism, loss of consciousness, coma develops.
Treatment: removal of the drug, gastric lavage, taking activated charcoal. Shown forced diuresis. With a pronounced decrease in blood pressure, with the collapse of the patient lay with his legs elevated. If necessary, intravenous administration of reopolyglukine or mezaton with the addition of angiotensinamide or 2% norepinephrine hydrotartrate solution is indicated. Adrenomimetic drugs prescribed with great caution because of the risk of pulmonary edema. 10% caffeine-sodium benzoate solution is injected subcutaneously. The presence of acute respiratory depression or its delay requires the suction of mucus from the respiratory tract, intubation and artificial respiration, oxygen therapy.
There are no specific antidotes for poisoning with roundin and other preparations of rauwolfia.
- Brand name: Raunatin
- Active ingredient: Rauwolfia alkaloids
- Dosage form: Pills.
- Manufacturer: Health Pharmaceutical Company
- Country of Origin: Ukraine
- Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients
- Liquid chromatographic method for the determination of sirolimus in blood using electrochemical detection
- Liquid chromatography-tandem mass spectrometry method for determination of Sirolimus coated drug eluting nano porous carbon stents
- Development of a validated high-throughput LC-ESI-MS method for determination of sirolimus on dried blood spots
- Determination of sirolimus in rabbit arteries using liquid chromatography separation and tandem mass spectrometric detection
- Stent-based antirestenotic coatings (sirolimus/paclitaxel)
- No delayed restenosis at 18 months after implantation of sirolimus-eluting stent
- Restenosis due to underexpansion of sirolimus-eluting stent in a bifurcation lesion
- Kissing sirolimus-eluting stents for the treatment of left main coronary artery stenosis
- Late stent thrombosis after implantation of a sirolimus-eluting stent
- Use of sirolimus-eluting coronary stents in routine clinical practice
- Synergistic use of sirolimus-eluting stents and intravascular ultrasound for the treatment of unprotected left main and vein graft disease
- Clinical and angiographic outcomes after overdilatation of undersized sirolimus-eluting stents with largely oversized balloons: An observational study
- Elective sirolimus-eluting stent implantation for left main coronary artery disease: Six-month angiographic follow-up and 1-year clinical outcome
- Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis
- Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: One-year clinical outcomes of 99 consecutive patients—the Rotterdam experience
- Single-digit target vessel revascularization in multivessel coronary interventions with sirolimus-eluting stents: Goodbye to coronary bypass grafting
- Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis
- Sirolimus- and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis
- Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?
- Results and follow-up after implantation of four or more sirolimus-eluting stents in the same patient
- Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia
- Mycotic aneurysm of left anterior descending artery after sirolimus-eluting stent implantation: A case report
- Underexpansion of sirolimus-eluting stents: Incidence and relationship to delivery pressure
8 other products in the same category:
arrow_upward